Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rozanolixizumab (UCB7665) in Moderate to Severe Generalized Myasthenia Gravis
2016-002698-36Phase 2Completed
- Sponsor
- UCB
- Start
- Nov 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in myasthenia gravis (MG) comparing Rozanolixizumab with Placebo (2 arms). Primary endpoint: Change from Baseline in Quantitative Myasthenia Gravis (QMG). Started Nov 2016; status: completed.
02
Drugs
rozanolixizumab
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on 2016-002698-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002698-36.